Method for early diagnosis of, and determination of prognosis in, cancer
First Claim
1. A method for diagnosis or prognosis for cancer associated with deletions of chromosome 9p21, the method comprising:
- (a) determining whether any portion of the 9p21 chromosome including and telomeric to sequence tagged site 3.21 is deleted; and
, (b) determining whether any portion of the 9p21 chromosome centromeric to sequence tagged site 3.21 is deleted;
wherein a positive finding in step (a) and a negative finding in step (b) are indicative of a cancer at an early stage and, wherein a positive finding in step (a) and a positive finding in step (b) are indicative of a cancer at an advanced stage, thereby determining a diagnosis or prognosis for cancer.
2 Assignments
0 Petitions
Accused Products
Abstract
The invention provides a method for diagnosis of, and determining a prognosis for, cancer causatively associated with derangements of chromosome 9p21. Underlying the invention is the discovery that such derangements have their genesis in deletions occurring centromeric to STS 3.21, most often including breakpoints in exon 8 and/or between exons 4 and 5 of the gene which codes for methylthioadenosine phosphorylase. As the cancer and tumor development advance, deletions in 9p21 progress centromerically from the genesis point toward the gene encoding p16. Thus, the method of the invention is performed by determining whether (a) portions of the 9p21 region including and telomeric to STS 3.21 are deleted; and (b) portions of the 9p21 region centromeric to STS 3.21 are deleted; wherein a positive finding in step (a) and a negative finding in step(b) are indicative of a cancer in an early stage of tumor development and a positive finding in step (b) is indicative of a cancer in an advanced stage of tumor development.
78 Citations
27 Claims
-
1. A method for diagnosis or prognosis for cancer associated with deletions of chromosome 9p21, the method comprising:
-
(a) determining whether any portion of the 9p21 chromosome including and telomeric to sequence tagged site 3.21 is deleted; and
,(b) determining whether any portion of the 9p21 chromosome centromeric to sequence tagged site 3.21 is deleted;
wherein a positive finding in step (a) and a negative finding in step (b) are indicative of a cancer at an early stage and, wherein a positive finding in step (a) and a positive finding in step (b) are indicative of a cancer at an advanced stage, thereby determining a diagnosis or prognosis for cancer. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8)
-
-
9. A method for diagnosis or prognosis for cancer associated with deletions of chromosome 9p21, the method comprising:
-
(a) determining whether any portion of the gene encoding metabolic enzyme mehylthioadenosine phosphphorylase is deleted; and
,(b) determining whether any portion of the 9p21 chromosome centromeric to sequence tagged site 3.21 is deleted;
wherein a positive finding in step (a) and a negative finding in step (b) are indicative of a cancer at an early stage and, wherein a positive finding in step (a) and a positive finding in step (b) are indicative of a cancer at an advanced stage, thereby determining a diagnosis or prognosis for cancer. - View Dependent Claims (10, 11, 12, 13, 14, 15, 16, 17, 18, 19)
-
-
20. A method for diagnosis of, and determining a prognosis for, cancer causatively associated with derangements of chromosome 9p21, the method comprising:
-
(a) determining whether any portion of the gene encoding metabolic enzyme mehylthioadenosine phosphphorylase is deleted; and
,(b) determining whether any portion of the gene coding for p16INK4A is deleted;
wherein a positive finding in step (a) and a negative finding in step (b) are indicative of a cancer at an early stage and, wherein a positive finding in step (a) and a positive finding in step (b) are indicative of a cancer at an advanced stage, thereby determining a diagnosis or prognosis for cancer. - View Dependent Claims (21, 22, 23, 24, 25, 26, 27)
-
Specification